We remain excited by the mounting evidence that certain types of recurrent cancerous brain tumors can be effectively treated with Cesium-131 brachytherapy, prolonging survival and improving quality of life at the same time.
From Lisa Esposito and Kristine Crane in U.S. News & World Report:
“[Cesium-131] implants provided stable tumor control and limited the risk of radiation side effects, according to the April 2017 Journal of Neurosurgery study. Cesium-131 brachytherapy implants result in less damage to healthy brain tissue than whole-brain radiation or stereotactic radiosurgery – high-dose, ultraprecise radiation such as Gamma Knife and CyberKnife – says study co-author Dr. Theodore Schwartz, a professor of neurosurgery with New York-Presbyterian and Weill Cornell Medicine.”
See more in U.S. News & World Report here.
ABS 2018 Lunch Symposium: Growing your Brachytherapy Programs: Leveraging Clinical Data, Clinician Relationships and Digital Efforts
For the second consecutive year, we are pleased to offer a lunch symposium for ABS 2018 attendees. This year we will discuss ways radiation oncologists, including brachytherapists, can grow their practices by efficiently, effectively leveraging newly available clinical data, expanding clinician relationships and putting digital marketing and search engine optimization to work.
Isoray’s VP Mike Krachon will be joined by Steven Kurtzman, MD and Paul Snyder, VP, Healthcare for digital marketing and public relations firm Write2Market. If you are attending ABS 2018, make sure this finds its way onto your calendar for Thursday, June 7 at 11:30 a.m.
IsoRay Announces the First Disposable Delivery System for Custom Intra-operative Strands for Prostate Cancer Treatment – Proprietary Design Will Offer Brachytherapists a New Affordable Option for Personalized Cesium-131 Treatments
The Build-Blu delivery system is a disposable, next-generation, seed stranding device that will allow prostate brachytherapists to affordably build custom-configured strands with Cesium-131 in the operating room, thereby allowing clinicians to individualize the procedure to the patient’s anatomy in real time. This new product will provide an alternative solution to the approximately 25% of treatment facilities for the prostate market that are using intra-operative techniques.
“Brachytherapists will no longer have to compromise preferred delivery of procedures over selecting Cesium-131,” says Isoray VP Mike Krachon. “With Build-Blu, we will have a delivery system that will allow clinicians the flexibility to do the procedure the way they want with Cesium-131 — bringing together the high energy, short half-life, forgiving energy and rapid side effects resolution Cesium-131 provides with an innovative new, disposable, stranding system.” Read more
Related: EBRT with brachytherapy matches surgery for Prostate Ca.
Take another look at Cesium-131 at ABS 2018
If you are not currently using it in your practice, are you willing to take a look at Cesium-131 brachytherapy and its high energy, short half-life and rapid side effect resolution for your patients? Contact customerservice@isoray.flywheelstaging.com to arrange a call, visit or meeting onsite at ABS 2018 in San Francisco.
